A Tyr-W-MIF-1 Analog Containing D-Pro2 Acts as a Selective μ2-Opioid Receptor Antagonist in the Mouse

The antagonistic properties of Tyr-d-Pro-Trp-Gly-NH2 (d-Pro2-Tyr-W-MIF-1), a Tyr-Pro-Trp-Gly-NH2(Tyr-W-MIF-1) analog, on the antinociception induced by the μ-opioid receptor agonists Tyr-W-MIF-1, [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO), Tyr-Pro-Trp-Phe-NH2 (endomorphin-1), and Tyr-Pro-Phe-Phe-NH2 (endomorphin-2) were studied in the mouse paw-withdrawal test. d-Pro2-Tyr-W-MIF-1 injected intrathecally (i.t.) had no apparent effect on the thermal nociceptive threshold. d-Pro2-Tyr-W-MIF-1 (0.1–0.4 nmol) coadministered i.t. showed a dose-dependent attenuation of the antinociception induced by Tyr-W-MIF-1 without affecting endomorphin- or DAMGO-induced antinociception. However, higher doses of d-Pro2-Tyr-W-MIF-1 (0.8–1.2 nmol) significantly attenuated endomorphin-1- or DAMGO-induced antinociception, whereas the antinociception induced by endomorphin-2 was still not affected by d-Pro2-Tyr-W-MIF-1. Pretreatment i.t. with various doses of naloxonazine, a μ1-opioid receptor antagonist, attenuated the antinociception induced by Tyr-W-MIF-1, endomorphin-1, endomorphin-2, or DAMGO. Judging from the ID50 values for naloxonazine against the antinociception induced by the μ-opioid receptor agonists, the antinociceptive effect of Tyr-W-MIF-1 is extremely less sensitive to naloxonazine than those of endomorphin-1 or DAMGO. In contrast, endomorphin-2-induced antinociception is extremely sensitive to naloxonazine. The present results clearly suggest that d-Pro2-Tyr-W-MIF-1 is the selective antagonist to be identified for the μ2-opioid receptor in the mouse spinal cord. d-Pro2-Tyr-W-MIF-1 may also discriminate between Tyr-W-MIF-1-induced antinociception and the antinociception induced by endomorphin-1 or DAMGO, all of which show a preference for the μ2-opioid receptor in the spinal cord.

[1]  K. Murayama,et al.  Endomorphin analogues containing D‐Pro2 discriminate different μ‐opioid receptor mediated antinociception in mice , 2002, British journal of pharmacology.

[2]  J. Fujimoto,et al.  d-Pro2-Endomorphin-1 andd-Pro2-Endomorphin-2, Respectively, Attenuate the Antinociception Induced by Endomorphin-1 and Endomorphin-2 Given Intrathecally in the Mouse , 2002, Journal of Pharmacology and Experimental Therapeutics.

[3]  K. Murayama,et al.  Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse. , 2001, European journal of pharmacology.

[4]  K. Murayama,et al.  Differential antagonism of endomorphin-1 and endomorphin-2 spinal antinociception by naloxonazine and 3-methoxynaltrexone , 2000, Brain Research.

[5]  K. Tan-No,et al.  Selective antagonism by naloxonazine of antinociception by Tyr-D-Arg-Phe-beta-Ala, a novel dermorphin analogue with high affinity at mu-opioid receptors. , 2000, European journal of pharmacology.

[6]  J. Kampine,et al.  Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. , 2000, The Journal of pharmacology and experimental therapeutics.

[7]  H. Ueda,et al.  Differential involvement of mu-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception. , 1999, European journal of pharmacology.

[8]  K. Tan-No,et al.  Contribution of spinal mu1-opioid receptors to morphine-induced antinociception. , 1999, European journal of pharmacology.

[9]  A. Kastin,et al.  A potent and selective endogenous agonist for the µ-opiate receptor , 1997, Nature.

[10]  J. Zadina,et al.  Analgesic effects of Tyr-W-MIF-1: a mixed mu2-opioid receptor agonist/mu1-opioid receptor antagonist. , 1996, European journal of pharmacology.

[11]  A. Kastin,et al.  Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by alpha 2-adrenoceptors. , 1996, European journal of pharmacology.

[12]  R. Olson,et al.  The Tyr-MIF-1 family of peptides , 1994, Neuroscience & Biobehavioral Reviews.

[13]  A. Kastin,et al.  Opiate receptor binding, guinea pig ileum activity, and prolonged analgesia induced by the brain peptide Tyr-W-MIF-1 and two potent analogs , 1994, Regulatory Peptides.

[14]  A. Kastin,et al.  Mu, delta, and kappa opiate receptor binding of Tyr-MIF-1 and of Tyr-W-MIF-1, its active fragments, and two potent analogs. , 1994, Life sciences.

[15]  A. Kastin,et al.  Prolonged analgesia after intracerebroventricular Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2) , 1993, Neuroscience Letters.

[16]  A. Kastin,et al.  Isolation of Tyr-W-MIF-1 from bovine hypothalami , 1993, Neuropeptides.

[17]  A. Kastin,et al.  Structure-activity relationships of analogs of the endogenous brain peptides Tyr-MIF-1 and Tyr-W-MIF-1. , 1993, Peptide research.

[18]  A. Kastin,et al.  Isolation of a novel tetrapeptide with opiate and antiopiate activity from human brain cortex: Tyr-Pro-Trp-Gly-NH2 (Tyr-W-MIF-1) , 1992, Peptides.

[19]  A. Kastin,et al.  Hemorphins, cytochrophins, and human beta-casomorphins bind to antiopiate (TYR-MIE-1) as well as opiate binding sites in rat brain. , 1990, Life sciences.

[20]  G. Pasternak,et al.  Naloxonazine actions in vivo. , 1986, European journal of pharmacology.

[21]  R. Goodman,et al.  Autoradiographic distribution of Mu1 and Mu2 opioid binding in the mouse central nervous system , 1985, Brain Research.

[22]  G. Pasternak,et al.  Irreversible opiate agonists and antagonists: the 14- hydroxydihydromorphinone azines , 1982, Journal of Neuroscience.

[23]  G. Pasternak,et al.  Classification of multiple morphine and enkephalin binding sites in the central nervous system. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Wilcox,et al.  Intrathecal morphine in mice: a new technique. , 1980, European journal of pharmacology.